Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis.
Hepatitis C virus
Hepatocellular carcinoma
Liver-related outcomes
Mortality
Non-invasive tests
Prognosis
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
25
03
2021
revised:
14
06
2021
accepted:
13
07
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
ppublish
Résumé
Liver fibrosis leads to liver-related events in patients with chronic hepatitis C (CHC) infection. Although non-invasive tests (NITs) are critical to early detection of the development of liver fibrosis, the prognostic role of NITs remains unclear due to the limited types of NITs and liver outcomes explored in previous studies. To determine the prognostic value of NITs for risk stratification in CHC patients. The protocol was registered in PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42019128176). The systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Search was performed using MEDLINE and EMBASE databases under a timeframe from the inception of the databases through February 25, 2020. We restricted our search to CHC cohort studies reporting an association between liver fibrosis assessed by NITs and the development of hepatocellular carcinoma, decompensation, or mortality. Pooled hazard ratios (HR) and area under the receiver operating characteristic (AUROC) for each NIT were estimated using a random effects model. Subgroup analyses were performed for NITs assessed at pre-treatment or post-treatment with sustained virologic response (SVR), treatment with either pegylated interferon and ribavirin or direct acting antiviral, Eastern or Western countries, and different cutoff points. The present meta FIB-4, APRI, and LSM showed potential for risk stratification in CHC patients. Cutoff levels need further validation.
Sections du résumé
BACKGROUND
BACKGROUND
Liver fibrosis leads to liver-related events in patients with chronic hepatitis C (CHC) infection. Although non-invasive tests (NITs) are critical to early detection of the development of liver fibrosis, the prognostic role of NITs remains unclear due to the limited types of NITs and liver outcomes explored in previous studies.
AIM
OBJECTIVE
To determine the prognostic value of NITs for risk stratification in CHC patients.
METHODS
METHODS
The protocol was registered in PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42019128176). The systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Search was performed using MEDLINE and EMBASE databases under a timeframe from the inception of the databases through February 25, 2020. We restricted our search to CHC cohort studies reporting an association between liver fibrosis assessed by NITs and the development of hepatocellular carcinoma, decompensation, or mortality. Pooled hazard ratios (HR) and area under the receiver operating characteristic (AUROC) for each NIT were estimated using a random effects model. Subgroup analyses were performed for NITs assessed at pre-treatment or post-treatment with sustained virologic response (SVR), treatment with either pegylated interferon and ribavirin or direct acting antiviral, Eastern or Western countries, and different cutoff points.
RESULTS
RESULTS
The present meta
CONCLUSION
CONCLUSIONS
FIB-4, APRI, and LSM showed potential for risk stratification in CHC patients. Cutoff levels need further validation.
Identifiants
pubmed: 34552701
doi: 10.4254/wjh.v13.i8.949
pmc: PMC8422917
doi:
Types de publication
Journal Article
Langues
eng
Pagination
949-968Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors deny any conflicts of interest.
Références
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9
pubmed: 23954643
Hepatology. 2015 May;61(5):1503-11
pubmed: 25545020
PLoS One. 2019 Jan 25;14(1):e0211286
pubmed: 30682180
Clin Infect Dis. 2015 Mar 15;60(6):950-8
pubmed: 25422386
J Hepatol. 2020 Mar;72(3):472-480
pubmed: 31629779
Hepatol Res. 2019 Feb;49(2):136-146
pubmed: 30335208
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
Clin Interv Aging. 2016 Aug 01;11:1035-41
pubmed: 27536084
Int J Mol Sci. 2016 Dec 20;17(12):
pubmed: 27999409
J Gastroenterol Hepatol. 2019 May;34(5):921-928
pubmed: 30393960
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
J Gastroenterol. 2016 Apr;51(4):380-9
pubmed: 26342600
AIDS. 2017 Feb 20;31(4):493-500
pubmed: 27922855
World J Hepatol. 2014 Dec 27;6(12):930-8
pubmed: 25544880
Open Forum Infect Dis. 2016 Oct 3;3(4):ofw212
pubmed: 27833930
Hepatol Int. 2017 Jul;11(4):401-408
pubmed: 28634687
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
PLoS One. 2018 Apr 19;13(4):e0195173
pubmed: 29672518
PLoS One. 2019 Feb 11;14(2):e0212036
pubmed: 30742668
Hepatology. 2006 Nov;44(5):1086-97
pubmed: 17058238
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Eur J Gastroenterol Hepatol. 2020 Mar;32(3):378-385
pubmed: 32011388
Am J Gastroenterol. 2010 Jun;105(6):1346-53
pubmed: 20179698
Clin Infect Dis. 2017 Jul 15;65(2):235-243
pubmed: 28329108
Ultrasound Med Biol. 2011 Sep;37(9):1361-73
pubmed: 21775051
AIDS. 2012 Mar 13;26(5):599-607
pubmed: 22156972
Gut Liver. 2016 May 23;10(3):429-36
pubmed: 26347515
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127
pubmed: 30334263
Dig Dis Sci. 2019 Oct;64(10):3013-3019
pubmed: 30937719
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1387-1396
pubmed: 31033848
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
J Gastroenterol Hepatol. 2014 Jan;29(1):137-43
pubmed: 24117602
Gastroenterol Hepatol (N Y). 2011 Jul;7(7):445-54
pubmed: 22298979
PLoS One. 2017 Sep 7;12(9):e0184404
pubmed: 28880930
J Viral Hepat. 2019 Jul;26(7):893-899
pubmed: 30974045
Gut Liver. 2016 Sep 15;10(5):796-802
pubmed: 27114418
J Formos Med Assoc. 2019 Jan;118(1 Pt 3):504-513
pubmed: 30527565
J Viral Hepat. 2019 Nov;26(11):1257-1265
pubmed: 31243878
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
J Gastroenterol. 2014 Nov;49(11):1495-503
pubmed: 24337828
J Hepatol. 2018 Sep;69(3):575-583
pubmed: 29709676
J Interferon Cytokine Res. 2019 Nov;39(11):703-710
pubmed: 31216229
Oncology. 2016;91(6):341-347
pubmed: 27694754
Gastroenterology. 2008 Jul;135(1):32-40
pubmed: 18471441
Hepat Med. 2018 Apr 03;10:13-22
pubmed: 29662329
Hepatol Res. 2020 Apr;50(4):426-438
pubmed: 31785120
Biosci Trends. 2019 Mar 14;13(1):32-39
pubmed: 30726798
Hepatology. 2009 Jun;49(6):1954-61
pubmed: 19434742
Hepatol Res. 2019 Dec;49(12):1441-1450
pubmed: 31373093